MedTrace Logo

Preventive Treatment of Episodic and Chronic Migraine

NCT01319825 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2011-03-22

No results posted yet for this study

Summary

This is an open label pilot study to determine whether milnacipran can reduce headache frequency in episodic and chronic migraine sufferers.

Conditions

  • Migraine With Aura
  • Migraine Without Aura
  • Chronic Migraine

Interventions

DRUG

milnacipran

100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.

Sponsors & Collaborators

  • California Medical Clinic for Headache

    lead OTHER

Principal Investigators

  • David B Kudrow, MD · California Medical Clinic for Headache

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-05-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319825 on ClinicalTrials.gov